Eukaryotic transcription activators stimulate the expression of specific sets of target genes through recruitment of co-activators such as the RNA polymerase II-interacting Mediator complex 1,2 . Aberrant function of transcription activators has been implicated in several diseases. However, therapeutic targeting efforts have been hampered by a lack of detailed molecular knowledge of the mechanisms of gene activation by disease-associated transcription activators. We previously identified an activator-targeted threehelix bundle KIX domain in the human MED15 Mediator subunit that is structurally conserved in Gal11/Med15 Mediator subunits in fungi 3,4 . The Gal11/Med15 KIX domain engages pleiotropic drug resistance transcription factor (Pdr1) orthologues, which are key regulators of the multidrug resistance pathway in Saccharomyces cerevisiae and in the clinically important human pathogen Candida glabrata 5,6 . The prevalence of C. glabrata is rising, partly owing to its low intrinsic susceptibility to azoles, the most widely used antifungal agent 7,8 . Drug-resistant clinical isolates of C. glabrata most commonly contain point mutations in Pdr1 that render it constitutively active 9-14 , suggesting that this transcriptional activation pathway represents a linchpin in C. glabrata multidrug resistance. Here we perform sequential biochemical and in vivo high-throughput screens to identify small-molecule inhibitors of the interaction of the C. glabrata Pdr1 activation domain with the C. glabrata Gal11A KIX domain. The lead compound (iKIX1) inhibits Pdr1-dependent gene activation and re-sensitizes drug-resistant C. glabrata to azole antifungals in vitro and in animal models for disseminated and urinary tract C. glabrata infection. Determining the NMR structure of the C. glabrata Gal11A KIX domain provides a detailed understanding of the molecular mechanism of Pdr1 gene activation and multidrug resistance inhibition by iKIX1. We have demonstrated the feasibility of small-molecule targeting of a transcription factorbinding site in Mediator as a novel therapeutic strategy in fungal infectious disease.
| Discovery of inhibitors of the CgGal11A KIX-CgPdr1AD interaction. a, Schematic of the screening process. b, iKIX1 inhibits cell growth in a concentration-dependent manner in the presence of 5 μM ketoconazole (KET); error bars represent means ±s.d. from duplicate plates. c, iKIX1 structure. d, Fluorescence polarization titration curve showing the interaction of CgGal11A KIX domain with CgPdr1 AD30 fitted to a dissociation constant (K d ) value of 319.7 nM ± 9.5 nM (left). iKIX1 competes out CgPdr1 AD30 with an half-maximum inhibitory concentration (IC 50 ) value of 190.2 μM ± 4.1 μM (right). The measured K d and IC 50 values were used to calculate an apparent inhibition constant (K i ) value of 18.1 μM for iKIX1. Data represent mean of two replicates and standard error from the fit is shown. LETTER RESEARCH identify hits with in vivo efficacy ( Fig. 1a ). We identified 5 compounds that reproducibly inhibited growth in a concentration-dependent manner only in the presence of ketoconazole (Extended Data Fig. 1 ). The most potent compound is referred to as iKIX1 (Fig. 1b, c) . In vitro binding studies revealed that the K d of the CgPdr1 AD for the CgGal11A KIX domain is 0.32 μM and the apparent K i for iKIX1 is 18 μM (Fig. 1d) .
To facilitate the elucidation of the mechanism of action of iKIX1, we determined the high-resolution solution structure of the CgGal11A KIX domain with a backbone root mean square deviation (r.m.s.d.) of 0.7 Å ( Fig. 2 and Extended Data Table 1 ; PDB ID 4D7X). The CgGal11A KIX domain has 51% sequence identity and 61% similarity with the S. cerevisiae Gal11/Med15 KIX domain 3 with an overall r.m.s.d. of 2.0 Å ( Fig. 2a and Extended Data Fig. 2c ). The CgGal11A KIX domain forms a three-helix bundle harbouring an extensively hydrophobic core and a short helix at the N terminus ( Fig. 2a ). We determined interaction interfaces of the CgGal11A KIX domain with the CgPdr1 AD and iKIX1 ( Fig. 2b ) by chemical shift perturbation (CSP) analysis. The CgPdr1 AD and iKIX1 target the same large hydrophobic groove harboured by the three helices. Residues from all three helices constitute the interaction interface, and titration of an isoleucine, leucine, valine (ILV)-methyl labelled CgGal11A KIX domain reveals large CSPs on the three leucines (L19, L23 and L51) upon addition of CgPdr1 AD and iKIX1 (Extended Data Fig. 2b ). The basic interaction interface on the KIX domain complements the acidic residues of CgPdr1 AD ( Fig. 2c ). Residues of the CgGal11A KIX domain that interact with CgPdr1 AD and iKIX1 overlap strongly, suggesting direct competitive binding as the mechanism of inhibition. Docking of iKIX1 to the CgGal11A KIX domain suggests extensive hydrogen bonding and hydrophobic interactions between iKIX1 and KIX domain residues ( Fig. 2d and Extended Data Fig. 2a ), matching the interaction interface mapped by CSP analysis.
To assess the in vivo effects of iKIX1 on Pdr1-dependent transcription, we initially used a strain in which the two S. cerevisiae PDR1 orthologues (ScPDR1 and ScPDR3) are deleted and which carries a plasmid expressing CgPDR1 3 , and a heterologous luciferase gene driven by 3 pleiotropic drug response elements (PDREs). Luciferase activity was strongly induced by ketoconazole treatment; iKIX1 co-treatment was able to block this induction in a concentration-dependent manner ( Fig. 3a) .
A chromatin immunoprecipitation (ChIP) assay was used to examine Gal11/Med15 recruitment to Pdr1-regulated target genes in S. cerevisiae after iKIX1 treatment. Gal11/Med15 was rapidly recruited to the promoters of the Pdr1 target genes PDR5 and SNQ2 after ketoconazole addition; in contrast, ketoconazole-induced recruitment of Gal11/Med15 was abrogated when the cells were pre-treated with iKIX1 ( Fig. 3b , Extended Data Fig. 3a ). iKIX1 did not impede the constitutive occupancy of Pdr1 at the same Pdr1-regulated target genes (Extended Data Fig. 3b ). Consistent with the ChIP data, iKIX1 strongly inhibited 
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azole-induced transcription of ScPdr1 target genes ( Fig. 3c , Extended Data Fig. 3a , c). Next, we determined the effect of iKIX1 on the transcription of C. glabrata Pdr1-regulated genes involved in drug efflux and multidrug resistance (CgCDR1, CgCDR2 and CgYOR1). CgPdr1 targets were strongly upregulated after ketoconazole treatment 10, 12 . However, pre-treatment with iKIX1 reduced target gene induction in a durable and concentration-dependent manner ( Fig. 3d and Extended Data Fig. 4a , b). Treatment with iKIX1 alone did not significantly affect Pdr1target gene induction (Extended Data Fig. 4c, d ).
Next-generation RNA sequencing (RNA-seq) was employed to query the genome-wide effects of iKIX1 and azole treatments alone and in combination on the transcriptome in both S. cerevisiae and in C. glabrata. In accord with previous reports 10, 16 , azole treatment upregulates Pdr1-dependent genes in both yeasts, such as the drug efflux pumps ScPDR5 and CgCDR1 (Supplementary Tables 1 and 2) . Combined azole and iKIX1 treatment strongly blunted expression of many azole-activated and Pdr1-dependent genes in both S. cerevisiae and C. glabrata (Fig. 3e , Extended Data Fig. 3d and Supplementary  Tables 1 and 2) , consistent with prior data and the proposed mechanism of action of iKIX1. iKIX1 alone affected very different sets of genes in S. cerevisiae and C. glabrata (Supplementary Tables 1-3) . Treatment of S. cerevisiae and C. glabrata cells with iKIX1 did not significantly alter the expression of PDR1 or GAL11/MED15 after azole treatment (Extended Data Fig. 3e ). Together, these findings suggest that the primary mechanism of synergistic antifungal effects of iKIX1 with azoles is through blocking the azole-stimulated and Pdr1-dependent drug efflux pathway.
To ascertain iKIX1 efficacy in azole-resistant C. glabrata strains, we examined the effects of iKIX1 on CgPdr1 target gene expression in a set of isogenic strains with gain-of-function CgPDR1 mutations originally identified in azole-resistant C. glabrata clinical isolates 9 . iKIX1 reduced azole-induced transcription of CgPdr1 target genes (for example, CgCDR1) in a concentration-dependent manner in all strains tested ( Fig. 3f and Extended Data Fig. 4d ).
To investigate whether these transcriptional effects translated to functional effects on drug efflux rates, we used the fluorescent compound rhodamine 6 G, a substrate of the CgCdr1 efflux pump 17, 18 . Maximum efflux rates were significantly decreased in PDR1 wild-type or gain-of-function strains pre-treated with iKIX1, as compared to vehicle control ( Fig. 3g and Extended Data Fig. 5 ).
Owing to its ability to reduce efflux pump gene expression and pump activity, we predicted that iKIX1 could restore azole-sensitivity to CgPDR1 gain-of-function mutant strains. Isogenic C. glabrata strains with wild-type or single gain-of-function alterations across CgPdr1 (Fig. 4a ) were tested for their sensitivity to fluconazole or ketoconazole on gradient plates with increasing concentrations of iKIX1 or vehicle. As expected, a CgPDR1 wild-type strain was sensitive to both fluconazole and ketoconazole, whereas CgPDR1 gain-of-function mutant strains grew robustly in the presence of azoles. iKIX1 restored azole-sensitivity to PDR1 gain-of-function mutant strains in a concentration-dependent manner (Fig. 4b) . CgPDR1 wild-type strains also exhibited increased growth inhibition in the presence of both iKIX1 and azole versus single agents alone (Extended Data Fig. 6a, b) .
On the basis of the strong combination effect of azoles and iKIX1 in the CgPDR1 L280F mutant we focused follow-up studies on this mutant strain. To investigate whether azoles and iKIX1 act in a synergistic or additive manner in CgPDR1 wild-type and CgPDR1 L280F mutant strains, we assessed growth in checkerboard assays with ketoconazole and iKIX1. In the wild-type CgPDR1 strain, the combination LETTER RESEARCH of ketoconazole and iKIX1 was additive (Extended Data Fig. 6c ). However, the CgPDR1 L280F mutant exhibited synergistic growth inhibition with iKIX1 and ketoconazole combination treatment, with combination indices <1 (Extended Data Fig. 6d ), in concordance with the spot-plating assay.
We carried out a limited analysis exploring the chemical space around the iKIX1 scaffold using commercial and custom synthesized iKIX1 analogues, identifying several compounds that lost activity in all assays; one analogue (A2) is shown in Extended Data Fig. 7a-d .
This example, together with data from iKIX1 analogues and the docked structure of iKIX1 to the CgGal11A KIX domain, supports a model where iKIX1 engages the core of the KIX domain using an array of hydrophobic and hydrogen-bond contacts.
We used two metazoan model systems to evaluate the potential utility of iKIX1 as a co-therapeutic with fluconazole to treat disseminated C. glabrata infection. The larvae of the moth Galleria mellonella has been used as a model to test the pathogenicity of a wide variety of human pathogens 19 . We used a G. mellonella survival assay to determine the virulence of C. glabrata PDR1 wild-type or PDR1 L280F strains in the presence of fluconazole, iKIX1, or a combination of the two (Fig. 4c ). Larvae were injected with C. glabrata and a single injection of fluconazole (50 mg kg −1 ), iKIX1 (25 mg kg −1 ), a combination of the two, or vehicle; survival was monitored every 24 h. G. mellonella injected with wild-type CgPDR1 was sensitive to fluconazole alone, and exhibited no significant alterations in survival with a fluconazole-iKIX1 combination. However, in G. mellonella larvae injected with a CgPDR1 L280F strain, whereas the single agents fluconazole or iKIX1 did not significantly increase survival compared to vehicle, co-treatment with iKIX1 and fluconazole significantly increased survival (P < 0.001).
Prior to mammalian studies, we sought to evaluate the potential toxicity of iKIX1 in mammalian cells (Extended Data Fig. 7e, f) . Human HepG2 cells treated with iKIX1 revealed toxicity only at high concentrations of iKIX1 (IC 50 ≈ 100 μM). iKIX1 had no effect on the transcription of SREBP-target genes at concentrations up to 100 μM, indicating its specificity for the fungal Gal11/Med15 KIX domain 4 . We also assessed the in vitro stability and in vivo mouse pharmacokinetics of iKIX1 and found that iKIX1 exhibited favourable drug-like properties and in vivo exposure in these studies (Extended Data Fig. 8 g, h) .
To evaluate the therapeutic potential of iKIX1 and azole antifungal co-therapy in a mammalian model, we initially turned to an established mouse model of disseminated fungal disease 11 . Mice were inoculated with C. glabrata by tail-vein injection and were dosed peritoneally oncedaily with 100 mg kg −1 fluconazole (high FLU), 100 mg kg −1 iKIX1, a combination of the two, or vehicle alone. After 7 days, mice injected with a CgPDR1 wild-type strain exhibited significantly reduced tissue fungal burden in the kidney and spleen following fluconazole treatment alone; iKIX1 co-treatment did not result in further reductions (Fig. 4d ). In contrast, in mice injected with the azole-resistant CgPDR1 L280F strain, only co-treatment with iKIX1 and fluconazole resulted in significant (~tenfold) reductions in fungal burdens in the kidney and spleen (P < 0.0001) ( Fig. 4d) . Similar results were observed with the clinically isolated CgPDR1 + and CgPDR1 L280F strains DSY562 and DSY565 (Extended Data Fig. 8a) . Consistent with previous studies 9 , the fungal burden in mice infected with the CgPDR1 L280F strain was higher than those infected with wild-type CgPDR1 strains, suggesting that PDR1 mutant strains may be more virulent in vivo. Similar but less pronounced results were found in mice injected with a CgPDR1 P822L strain (Extended Data Fig. 8b) . When mice were injected with a CgPDR1 wild-type strain and dosed with 25 mg kg −1 fluconazole (low FLU) alone or in combination with iKIX1, fluconazole alone poorly reduced tissue burden, whereas combination treatment resulted in significant (~tenfold) reductions in fungal burdens in both organs (P < 0.0001) (Fig. 4d) . These results suggest that iKIX1 combination treatment with azole may be therapeutically desirable even in the absence of CgPDR1 gain-of-function mutations. Mice infected with a Cgpdr1 null strain were more sensitive to iKIX1 alone; unlike mice infected with CgPDR1 + or CgPDR1 L280F strains, low doses of iKIX1 did not further reduce fungal burden in Cgpdr1 null infections (Extended Data Fig. 8c, d) .
CgPDR1 gain-of-function mutations are also known to control adherence to host cells 20 . As previously observed 20 , a PDR1 L280F mutant increased relative adherence to epithelial cells as compared to a PDR1 wild-type strain. Strikingly, iKIX1 treatment alone reduced adherence to levels similar to a PDR1 wild-type strain (Extended Data Fig. 8e ). Ketoconazole alone or co-treatment with iKIX1 also reduced relative adherence to levels comparable to a PDR1 wild-type strain. To assess (SFY115, n = 9 ). For SFY114, n = 10. *P < 0.05, ***P < 0.001 as compared to PBS vehicle control. Statistical differences measured using a log-rank (Mantel-Cox) test. d, iKIX1 combination treatment with 25 mg kg −1 fluconazole (low FLU) reduces fungal tissue burden in the kidney or spleen of mice injected with CgPDR1 wild-type (SFY114); iKIX1 in combination with 100 mg kg −1 fluconazole (high FLU) reduces fungal tissue burden in the kidney or spleen of mice injected with CgPDR1 L280F (SFY115). n = 5 mice for each treatment condition; *P < 0.05, **P < 0.005 and ***P < 0.0001 as compared to no treatment. Statistical differences measured using a Wilcoxon rank-sum test; error bars represent means ±s.d. 
the role of iKIX1 in modulating adhesion in an infection model, we turned to a mouse model of urinary tract infection 21 . In both the bladder and kidney, iKIX1 alone was sufficient to decrease fungal load after infection with either a PDR1 wild-type strain or a PDR1 L280F strain (Extended Data Fig. 8f ), suggesting that iKIX1 may indeed modulate adhesion.
The proportion of azole-resistant C. glabrata (up to 20% in the US) and the emergence of multidrug resistance (approximately 40% of echinocandin-resistant isolates are azole-resistant) shows the need for novel treatments that can target these resistant populations 22, 23 . Our results demonstrate that small-molecule disruption of the interaction between the CgGal11A KIX domain and the CgPdr1 activation domain is a therapeutically tractable method for resensitizing azole-resistant C. glabrata to standard azole antifungal treatment (Extended Data Fig. 9 ).
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper. Figure 6 | iKIX1 increases the sensitivity of Cg strains bearing wild-type CgPDR1 to azole treatment and synergistically enhances azole sensitivity in a CgPDR1 L280F mutant strain. a, b, Two strains bearing wild-type CgPDR1 alleles (SFY114, DSY759) were plated at concentrations differing by tenfold (10×, 1×) on plates containing increasing concentrations of iKIX1 to 300 μM in the presence or absence of 1 μM ketoconazole (a) or iKIX1 to 250 μM in the presence or absence of 50 μM fluconazole (b). c, iKIX1 and ketoconazole have additive effects on the growth of a CgPDR1 wild-type strain. d, iKIX1 and ketoconazole synergistically inhibit the growth of the CgPDR1 L280F mutant. c, d, The EUCAST broth microdilution method 25 was used to assess the effects of iKIX1 and ketoconazole combination treatment. Growth, as assessed by A 540 nm , was normalized to no drug control. All combination indices (CI) for the CgPDR1 L280F mutant were less than 1, indicating synergy. A representative of three biological replicates is shown and the red line indicates a combination index of 1.
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Extended Data Figure 7 | iKIX1 exhibits favourable drug-like properties and an inactive analogue highlights the importance of the electron withdrawing chloride groups on the aromatic ring of iKIX1. a-d, A structurally similar iKIX1 analogue (A2) lacking electronwithdrawing groups increases the IC 50 in the fluorescence polarization assay (a) and abolishes activity in the S. cerevisiae luciferase reporter assay (b), repression of CgCDR1 expression (c), and synergistic C. glabrata cell growth inhibition with azoles (d). Error bars in b, c indicate mean ±s.d. of technical replicates (reads/real-time PCR reactions, respectively). **P < 0.005; statistical differences calculated using two-tailed Student's t-test. e, iKIX1 inhibits viability of HepG2 cells at concentrations >50 μM. The mean of 3 biological replicates is shown; error bars represent means ±s.d. f, iKIX1 exhibits no effect on transcription of SREBP-target genes in HepG2 cells at concentrations up to 100 μM. Biological duplicates were assessed; representative experiment is shown and error bars represent means ±s.d. of technical (real-time PCR) replicates. g, Mouse plasma stability of iKIX1 and mouse and human microsomal stability of iKIX1, n = 1. h, In vivo pharmacokinetic parameters of iKIX1, n = 3 mice per time point.
